ADMA Biologics Securities Fraud Lawsuit Deadline Approaches
Investors in ADMA Biologics (NASDAQ: ADMA) who experienced losses exceeding $100,000 between August 9, 2024, and March 25, 2026, face a critical lead plaintiff deadline of August 10, 2026. The Rosen Law Firm is leading a securities fraud class action alleging undisclosed related party transactions and channel stuffing. This matters now as affected investors must act by the August 10 deadline to potentially lead the litigation and seek compensation without upfront costs.
ADMA Biologics investors with losses exceeding $100,000 between August 9, 2024, and March 25, 2026, should consider engaging legal counsel to potentially serve as lead plaintiff in a securities fraud class action lawsuit by the August 10, 2026 deadline.